methylphenidateWhat was measured
Measured, with no finding
626 endpoints
Show what was measuredHide what was measured
decreased appetite, number needed to treat
increases
For example, clinicians only need to treat 4 children to identify an episode of decreased appetite
PMID 11762571 · one of two readings recorded this
hyperactivity index, parent reported
decreases
Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67)
PMID 11762571 · one of two readings recorded this
hyperactivity index reported by teacher and by parent, pooled effect size; decreased appetite as an adverse event
effect size reported by teacher 0.78, 95% CI 0.64-0.91; reported by parent 0.54, 95% CI 0.40-0.67
Not recorded as a finding: this platform holds no node for the endpoint
Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67).
PMID 11762571 · one of two readings recorded this
hyperactivity index, teacher reported
decreases
Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67)
PMID 11762571 · one of two readings recorded this
ADHD symptom severity on the ADHDRS-IV Parent:Inv, standardised mean difference of methylphenidate versus atomoxetine; response rate; all-cause discontinuation
no effect, SMD 0.09 (95% CI -0.08-0.26), p = 0.29
Not recorded as a finding: the comparison was against another active treatment
Meta-analysis did not find a significant difference in efficacy between methylphenidate and atomoxetine when standardized mean difference (SMD) was used as a measure of effect size 0.09 (95% CI -0.08-0.26) (Z = 1.06, p = 0.29).
PMID 22074258 · one of two readings recorded this
ADHDRS-IV Parent:Inv efficacy, pooled SMD
no effect, p = 0.29, n = 2762
Meta-analysis did not find a significant difference in efficacy between methylphenidate and atomoxetine when standardized mean difference (SMD) was used as a measure of effect size 0.09 (95% CI -0.08-0.26) (Z = 1.06, p = 0.29)
PMID 22074258 · one of two readings recorded this
ADHDRS-IV Parent:Inv efficacy, pooled SMD
no effect, p = 0.64
Immediate release methylphenidate was not superior to atomoxetine SMD -0.04 (95% CI -0.19-0.12) (Z = 0.46, p = 0.64)
PMID 22074258 · one of two readings recorded this
ADHDRS-IV Parent:Inv efficacy, pooled SMD
no effect, p = 0.22
Excluding the cross over trial too did not change the results significantly 0.11 (95% CI -0.07-0.29) (Z = 1.23 p = 0.22)
PMID 22074258 · one of two readings recorded this
ADHDRS-IV Parent:Inv efficacy, pooled SMD
no effect, p = 0.2
Excluding open label trials did not significantly alter the pooled standardized mean difference 0.08 (95% CI -0.04-0.21) (Z = 1.27, p = 0.20)
PMID 22074258 · one of two readings recorded this
ADHDRS-IV Parent:Inv efficacy, pooled SMD
increases, p = 0.002
Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate 0.32 (95% CI 0.12-0.53 (Z = 3.05, p < 0.002)
PMID 22074258 · one of two readings recorded this
all-cause discontinuation
no effect, p = 0.25
There was no significant difference in all cause discontinuation between atomoxetine and methylphenidate (RR 1.22, 95% CI 0.87-1.71, p = 0.25)
PMID 22074258 · one of two readings recorded this
between-study heterogeneity of SMD
unclear, p = 0.002
There was significant heterogeneity among the studies (p = 0.002, I2 = 67%)
PMID 22074258 · one of two readings recorded this
between-study heterogeneity of SMD
no effect, p = 0.48
There was no significant heterogeneity among double blind trials (p = 0.48 I2 = 0%)
PMID 22074258 · one of two readings recorded this
between-study heterogeneity of SMD
unclear, p = 0.001
Subgroup analysis found that the heterogeneity was due to the open label trials (p = 0.001, I2 = 81%)
PMID 22074258 · one of two readings recorded this
response rate
no effect, p = 0.49
There was no significant difference in response rates between the two medications (RR = 0.93 95% CI 0.76-1.14, p = 0.49)
PMID 22074258 · one of two readings recorded this
adverse effect anorexia
increases, p = 0.02
Anorexia | 2 | 121/123 | 2.18 [1.15, 4.14] | 0.02 | 0
PMID 24416225 · one of two readings recorded this
adverse effect anxiety
increases, p = 0.005
Anxiety | 2 | 145/148 | 2.50 [1.32, 4.73] | 0.005 | 0
PMID 24416225 · one of two readings recorded this
adverse effect insomnia
no effect, p = 0.23
Insomnia | 2 | 128/131 | 1.46 [0.78, 2.74] | 0.23 | 0
PMID 24416225 · one of two readings recorded this
adverse effect nausea
increases, p = 0.001
Nausea | 2 | 110/112 | 4.65 [1.84, 11.77] | 0.001 | 0
PMID 24416225 · one of two readings recorded this
adverse effect tachycardia
no effect, p = 0.47
Tachycardia | 3 | 96/100 | 0.66 [0.21, 2.06] | 0.47 | 40
PMID 24416225 · one of two readings recorded this
adverse effect vertigo
increases, p = 0.004
Vertigo | 2 | 128/131 | 3.74 [1.52, 9.16] | 0.004 | 0
PMID 24416225 · one of two readings recorded this
baseline BFI, Moraska 2010
Moraska et al, 2010 | 62 | 63 | 40% | 60 | 4 | 54 | Mixed tumor | Fatigue | BFI: 3.36±1.54/3.4±1.72 | USA | parallel | 5
PMID 24416225 · one of two readings recorded this
baseline BFI, Roth 2010
Roth et al, 2010 | 10 | 13 | 100% | 70 | 6 | 30 | Prostate cancer | Fatigue | BFI: 5.13±2.25/4.01±2. 00 | USA | parallel | 3
PMID 24416225 · one of two readings recorded this
baseline FACT-F, Bruera 2006
Bruera et al, 2006 | 52 | 53 | 37% | 57 | 1 | 20 | Mixed tumor | Fatigue | FACT-F: 16.87±7.96/17.04±7.98 | USA | parallel | 5
PMID 24416225 · one of two readings recorded this
baseline FACT-F, Butler 2007
Butler et al, 2007 | 20 | 21 | 54% | 56 | 4 | 30 | Primary brain tumor | Fatigue | FACT-F: 34.7±8.04/33.3±12.92 | USA | parallel | 4
PMID 24416225 · one of two readings recorded this
baseline FACT-F, Lower 2009
Lower et al, 2009 | 54 | 69 | 10% | 53 | 8 | 28 | Mixed tumor | Fatigue | FACT-F: 30.9±10.2/30.0±10.1 | USA | parallel | 5
PMID 24416225 · one of two readings recorded this
BFI severity scores decrease
decreases, p = 0.03
greater decrease on BFI severity scores (p = 0.03)
PMID 24416225 · one of two readings recorded this
BFI total scores decrease
decreases, p = 0.03
a trend toward greater decrease on BFI total scores (p = 0.03)
PMID 24416225 · one of two readings recorded this
cancer-related fatigue, BFI
no effect, p = 0.23
The Other two studies used the BFI, with an overall mean difference of −0.69 (95% [CI] −1.81–0.43), suggesting no significant effect of methylphenidate on CRF (p = 0.23)
PMID 24416225 · one of two readings recorded this
cancer-related fatigue, FACT-F
decreases, p = 0.01
The overall mean difference was −3.13 (95% confidence interval [CI] −5.55– −0.71), suggesting significant effect of methylphenidate on CRF (p = 0.01)
PMID 24416225 · one of two readings recorded this
cancer-related fatigue, long-time treatment group
decreases, p = 0.03
Long-time group's overall mean difference was −3.70 (95% [CI] −7.03–−0.37; P = 0.03)
PMID 24416225 · one of two readings recorded this
cancer-related fatigue on FACT-F, pooled mean difference
MD -3.13, 95% CI -5.55 to -0.71, p = 0.01
Not recorded as a finding: direction carried only by a signed estimate; the sentence says 'significant effect' without a direction word
The overall mean difference was −3.13 (95% confidence interval [CI] −5.55– −0.71), suggesting significant effect of methylphenidate on CRF (p = 0.01).
PMID 24416225 · one of two readings recorded this
cancer-related fatigue, short-time treatment group
no effect, p = 0.17
short-time group's overall mean difference was −2.49 (95% [CI] −6.01–1.03; P = 0.17)
PMID 24416225 · one of two readings recorded this
cognition associated with cancer-related fatigue, pooled SMD across MMSE and HSCS
no effect, SMD -0.35, 95% CI -3.72 to 3.02, p = 0.84
Not recorded as a finding: no node for cognition pooled across MMSE and High Sensitivity Cognitive Screen
The pooled standardized mean difference demonstrated no impact of methylphenidate on cognition associated with CRF (−0.35, 95%CI −3.72–3.02, p = 0.84, I2 = 0%).
PMID 24416225 · one of two readings recorded this
cognition associated with CRF
no effect, p = 0.84
The pooled standardized mean difference demonstrated no impact of methylphenidate on cognition associated with CRF (−0.35, 95%CI −3.72–3.02, p = 0.84, I2 = 0%)
PMID 24416225 · one of two readings recorded this
depression associated with cancer-related fatigue, pooled SMD across ESAS-D and CES-D
no effect, SMD -0.09, 95% CI -1.13 to 0.95, p = 0.86
Not recorded as a finding: no node for depression symptom severity pooled across two named scales
The pooled standardized mean difference demonstrated no impact of methylphenidate on depression associated with CRF (−0.09, 95%CI −1.13–0.95, p = 0.86, I2 = 0%).
PMID 24416225 · one of two readings recorded this
depression associated with CRF
no effect, p = 0.86
The pooled standardized mean difference demonstrated no impact of methylphenidate on depression associated with CRF (−0.09, 95%CI −1.13–0.95, p = 0.86, I2 = 0%)
PMID 24416225 · one of two readings recorded this
FACT-F fatigue, methylphenidate versus placebo at day 8
no effect
no statistically significant difference was found between methylphenidate and placebo group on day 8
PMID 24416225 · one of two readings recorded this
study discontinuation due to side effects
no effect, p = 0.17
The overall risk ratio for study discontinuation due to side effects didn't suggest statistical significance between patients treated with methylphenidate and patients with placebo (RR 2.38, 95% CI 0.69–8.29, p = 0.17, I2 = 8%)
PMID 24416225 · one of two readings recorded this
decreased appetite and sleep problems as adverse events, risk ratio
increases, decreased appetite RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants
Not recorded as a finding: no node for specific non-serious adverse events; supplement-adverse-event-incidence is bound to oral or enteral supplements and any adverse event
Children in the methylphenidate group were at 60% greater risk for trouble sleeping/sleep problems (RR 1.60, 95% CI 1.15 to 2.23; 13 trials, 2416 participants), and 266% greater risk for decreased appetite (RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants) than children in the control group.
PMID 26599576 · one of two readings recorded this
decreased appetite
increases, n = 2962
266% greater risk for decreased appetite (RR 3.66, 95% CI 2.56 to 5.23; 16 trials, 2962 participants)
PMID 26599576 · one of two readings recorded this
non-serious adverse events, any, Trial Sequential Analysis adjusted
increases
The Trial Sequential Analysis-adjusted intervention effect was RR 1.29 (CI 1.06 to 1.56)
PMID 26599576 · one of two readings recorded this
non-serious adverse events, any
increases, n = 3132
This equates to a 29% increase in the overall risk of any non-serious adverse events (RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants; very low-quality evidence)
PMID 26599576 · one of two readings recorded this
parent-reported quality of life on CHQ
increases
The change reported in a meta-analysis of three trials corresponds to a MD of 8.0 points (95% CI 5.49 to 10.46) on the CHQ
PMID 26599576 · one of two readings recorded this
parent-reported quality of life
increases, n = 514
methylphenidate may improve parent-reported quality of life (SMD 0.61, 95% CI 0.42 to 0.80; 3 trials, 514 participants; very low-quality evidence)
PMID 26599576 · one of two readings recorded this
serious adverse events, pooled risk ratio
RR 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants
Not recorded as a finding: node serious-adverse-event-incidence exists but the only sentence is a one-sided negation ('no evidence ... increase'), which does not establish no_effect
There was no evidence that methylphenidate was associated with an increase in serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants; very low-quality evidence).
PMID 26599576 · one of two readings recorded this
serious adverse events, Trial Sequential Analysis adjusted
no effect
The Trial Sequential Analysis-adjusted intervention effect was RR 0.91 (CI 0.02 to 33.2)
PMID 26599576 · one of two readings recorded this
serious adverse events
no effect, n = 1532
There was no evidence that methylphenidate was associated with an increase in serious (e.g. life threatening) adverse events (risk ratio (RR) 0.98, 95% CI 0.44 to 2.22; 9 trials, 1532 participants; very low-quality evidence)
PMID 26599576 · one of two readings recorded this
sleep problems
increases, n = 2416
Children in the methylphenidate group were at 60% greater risk for trouble sleeping/sleep problems (RR 1.60, 95% CI 1.15 to 2.23; 13 trials, 2416 participants)
PMID 26599576 · one of two readings recorded this
teacher-rated ADHD symptoms, ADHD Rating Scale
decreases, SMD -0.77, 95% CI -0.90 to -0.64; 19 trials, 1698 participants
Not recorded as a finding: no node for ADHD symptom severity on the ADHD-RS or pooled across teacher scales
Methylphenidate may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.77, 95% confidence interval (CI) -0.90 to -0.64; 19 trials, 1698 participants; very low-quality evidence).
PMID 26599576 · both readings recorded this
teacher-rated ADHD symptoms on ADHD-RS
decreases
This corresponds to a mean difference (MD) of -9.6 points (95% CI -13.75 to -6.38) on the ADHD Rating Scale (ADHD-RS; range 0 to 72 points; DuPaul 1991a)
PMID 26599576 · one of two readings recorded this
teacher-rated ADHD symptoms
decreases, n = 1698
Methylphenidate may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.77, 95% confidence interval (CI) -0.90 to -0.64; 19 trials, 1698 participants; very low-quality evidence)
PMID 26599576 · one of two readings recorded this
teacher-rated general behaviour
decreases, n = 668
Teacher-rated general behaviour seemed to improve with methylphenidate (SMD -0.87, 95% CI -1.04 to -0.71; 5 trials, 668 participants; very low-quality evidence)
PMID 26599576 · one of two readings recorded this
ADHD symptoms by rater
decreases, n = 1826
observer rated (−0.61, −0.87 to −0.35, nine trials, 1826 participants)
PMID 26608309 · one of two readings recorded this
ADHD symptoms by rater
decreases, p = 0.37, n = 2179
parent rated (−0.65, −0.81 to −0.50, 21 trials, 2179 participants), test for subgroup difference, P=0.37
PMID 26608309 · one of two readings recorded this
ADHD symptoms by rater
decreases, n = 1689
teacher rated (−0.78, −0.93 to −0.63, 19 trials, 1689 participants)
PMID 26608309 · one of two readings recorded this
ADHD symptoms in crossover trials, carry-over analysis
decreases, n = 372
First period (−0.64, −0.85 to −0.44, four trials, 372 participants)
PMID 26608309 · one of two readings recorded this
ADHD symptoms in crossover trials, carry-over analysis
decreases, p = 0.1, n = 372
second period (−0.91, −1.18 to −0.65, four trials, 372 participants; test for subgroup difference, P=0.1)
PMID 26608309 · one of two readings recorded this
ADHD symptoms (parallel and first period crossover trials)
unclear, p = 0.05, n = 559
compared to the combined type (0.65, −1.30 to 2.60, two trials, 559 participants; test for subgroup difference, P=0.05)
PMID 26608309 · one of two readings recorded this
ADHD symptoms (parallel and first period crossover trials)
decreases, n = 204
a higher intervention effect for the inattentive subtype (standardised mean difference −1.31, 95% confidence interval −1.61 to −1.01, one trial, 204 participants)
PMID 26608309 · one of two readings recorded this
Decreased appetite (crossover trials)
increases, n = 3862
decreased appetite (3.04, 2.35 to 3.94, 35 trials, 3862 participants, I2=40%)
PMID 26608309 · one of two readings recorded this
Decreased appetite (parallel group trials)
increases, n = 2962
The most common non-serious adverse events were decreased appetite (risk ratio 3.66, 95% confidence interval 2.56 to 5.23, 16 trials, 2962 participants; I2=18%)
PMID 26608309 · one of two readings recorded this
General behaviour (crossover trials)
decreases, n = 2014
The crossover trial analysis also showed a beneficial treatment effect (standardised mean difference −0.69, 95% confidence interval −0.78 to −0.60, 16 trials, 2014 participants)
PMID 26608309 · one of two readings recorded this
Non-serious adverse events (crossover trials, end of second period)
increases, n = 2072
For these trials methylphenidate was associated with an overall increase in total number of non-serious adverse events (risk ratio 1.33, 95% confidence interval 1.11 to 1.58, 21 trials, 2072 participants)
PMID 26608309 · one of two readings recorded this
Non-serious adverse events (parallel group trials)
increases, n = 3132
Methylphenidate was associated with an overall risk of total number of non-serious adverse events by 29% (risk ratio 1.29, 95% confidence interval 1.10 to 1.51, 21 trials, 3132 participants, fig 5)
PMID 26608309 · one of two readings recorded this
Non-serious adverse events (parallel group trials)
no effect, p = 0.57
which did not seem to be related to dose (test for subgroup difference between low dose and high dose methylphenidate, P=0.57)
PMID 26608309 · one of two readings recorded this
Non-serious adverse events, trial sequential analysis adjusted
increases
The trial sequential analysis adjusted risk ratio was 1.29 (95% confidence interval 1.06 to 1.56)
PMID 26608309 · one of two readings recorded this
Publication bias, teacher-rated ADHD symptoms (Egger's test)
no effect, p = 0.81
No publication bias was detected (Egger’s test P=0.81)
PMID 26608309 · one of two readings recorded this
Quality of life, child health questionnaire mean difference
increases
which corresponds on the child health questionnaire scale to a mean difference of 8.0 points (95% confidence interval 5.49 to 10.46)
PMID 26608309 · one of two readings recorded this
quality of life on the child health questionnaire (parent-rated, three parallel-group trials), methylphenidate versus placebo or no intervention
increases, SMD 0.61, 95% CI 0.42 to 0.80, three trials, 514 participants, n = 514
Not recorded as a finding: the supporting sentence never names the compound
There was a small beneficial effect on quality of life (standardised mean difference 0.61, 95% confidence interval 0.42 to 0.80, three trials, 514 participants, fig 8), which corresponds on the child health questionnaire scale to a mean difference of 8.0 points (95% confidence interval 5.49 to 10.46), which is larger than the minimal clinical relevant difference of 7.0.
PMID 26608309 · one of two readings recorded this
Quality of life (parallel group trials)
increases, n = 514
There was a small beneficial effect on quality of life (standardised mean difference 0.61, 95% confidence interval 0.42 to 0.80, three trials, 514 participants, fig 8)
PMID 26608309 · one of two readings recorded this
Serious adverse events (crossover trials, end of last period)
no effect, n = 1721
These trials did not seem to differ between intervention groups (risk ratio 1.62, 95% confidence interval 0.34 to 7.71, 1721 participants; I2=0%, P=0.65)
PMID 26608309 · one of two readings recorded this
Serious adverse events (parallel group trials)
no effect, n = 1532
For these trials methylphenidate was not associated with an overall increase in total number of serious adverse events (risk ratio 0.98, 95% confidence interval 0.44 to 2.22, 1532 participants, fig 3)
PMID 26608309 · one of two readings recorded this
Serious adverse events, trial sequential analysis adjusted
no effect
The trial sequential analysis adjusted intervention effect is risk ratio 0.91% (95% confidence interval 0.02 to 33.2)
PMID 26608309 · one of two readings recorded this
Sleep problems (crossover trials)
increases, n = 3270
sleep problems (1.57, 1.20 to 2.06, 31 trials, 3270 participants, I2=47%)
PMID 26608309 · one of two readings recorded this
Sleep problems (parallel group trials)
increases, n = 2416
sleep problems (1.60, 1.15 to 2.23, 13 trials, 2416 participants; I2=0%)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms, ADHD rating scale mean difference
decreases
This corresponds to a mean difference of −9.6 points (95% confidence interval −13.75 to −6.38) on the ADHD rating scale
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms by scale type
unclear, p = 0.006
The intervention effect was significantly influenced by choice of scale (test for subgroup differences, P=0.006)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (end of last period crossover trials)
decreases, n = 5145
The end of last period crossover trials also showed a significant treatment effect, with a standardised mean difference of −0.93 (95% confidence interval −1.06 to −0.80, 59 trials, 5145 participants)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (end of last period crossover trials)
decreases, n = 3413
The benefit, however, was significantly greater with higher doses of methylphenidate (−0.98, −1.13 to −0.84, 36 trials, 3413 participants)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (end of last period crossover trials)
decreases, p = 0.02, n = 3408
compared to low doses (−0.73, −0.89 to −0.57, 42 trials, 3408 participants; test for subgroup difference, P=0.02)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (end of last period crossover trials)
no effect, p = 0.09
that was not significantly influenced by risk of bias (test for subgroup difference, P=0.09)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (parallel group trials)
decreases, n = 1698
The results showed an effect of methylphenidate on teacher rated symptoms in the parallel group trials (standardised mean difference −0.77, 95% confidence interval −0.90 to −0.64, 19 trials, 1698 participants, fig 2)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (parallel group trials)
decreases, n = 253
Long term trials had a smaller effect (standardised mean difference −0.47, 95% confidence interval −0.72 to −0.22, one trial, 253 participants)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (parallel group trials)
decreases, p = 0.04, n = 431
compared to trials including participants naive to the drugs (−0.63, −0.94 to −0.31, four trials, 431 participants; test for subgroup difference, P=0.04)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (parallel group trials)
decreases, n = 286
Trials including participants with previous use of drugs before randomisation resulted in a larger effect (−1.06, −1.33 to −0.79, two trials, 286 participants)
PMID 26608309 · one of two readings recorded this
Teacher-rated ADHD symptoms (parallel group trials)
decreases, p = 0.02, n = 1445
short term trials (−0.81, −0.94 to −0.68, 18 trials, 1445 participants; test for subgroup difference, P=0.02)
PMID 26608309 · one of two readings recorded this
teacher-rated ADHD symptoms, SMD pooled across scales (ADHD rating scale equivalent)
SMD -0.77, 95% CI -0.90 to -0.64; 19 trials, 1698 participants, n = 1698
Not recorded as a finding: no node for ADHD symptom severity pooled across teacher-rated scales
The results showed an effect of methylphenidate on teacher rated symptoms in the parallel group trials (standardised mean difference −0.77, 95% confidence interval −0.90 to −0.64, 19 trials, 1698 participants, fig 2).
PMID 26608309 · one of two readings recorded this
Teacher-rated general behaviour (parallel group trials)
decreases, n = 668
The standardised mean difference of teacher rated general behaviour in parallel group trials was −0.87 (95% confidence interval −1.04 to −0.71, five trials, 668 participants, fig 7)
PMID 26608309 · one of two readings recorded this
teacher-rated general behaviour, SMD pooled across psychometric instruments
SMD -0.87, 95% CI -1.04 to -0.71; five trials, 668 participants, n = 668
Not recorded as a finding: no node for general behaviour at school and home
The standardised mean difference of teacher rated general behaviour in parallel group trials was −0.87 (95% confidence interval −1.04 to −0.71, five trials, 668 participants, fig 7).
PMID 26608309 · one of two readings recorded this
total non-serious adverse events, pooled risk ratio, parallel group trials
increases, RR 1.29, 95% CI 1.10 to 1.51; 21 trials, 3132 participants, n = 3132
Not recorded as a finding: near miss: supplement-adverse-event-incidence is bound to oral or enteral supplements and adverse-reaction-incidence-ungraded to reactions attributed to the product; this is all non-serious events of any kind
Methylphenidate was associated with an overall risk of total number of non-serious adverse events by 29% (risk ratio 1.29, 95% confidence interval 1.10 to 1.51, 21 trials, 3132 participants, fig 5).
PMID 26608309 · one of two readings recorded this
total serious adverse events, pooled risk ratio, parallel group trials
RR 0.98, 95% CI 0.44 to 2.22; 1532 participants, n = 1532
Not recorded as a finding: node serious-adverse-event-incidence exists but the sentence is a one-sided negation ('not associated with an overall increase'), which does not establish no_effect
For these trials methylphenidate was not associated with an overall increase in total number of serious adverse events (risk ratio 0.98, 95% confidence interval 0.44 to 2.22, 1532 participants, fig 3).
PMID 26608309 · one of two readings recorded this
diastolic blood pressure change at 12 months
no effect
Arcieri et al. reported no statistically significant effects on DBP (+0.13 mmHg) and SBP (+0.36 mmHg) at 12 months in comparison with baseline
PMID 28236285 · one of two readings recorded this
diastolic blood pressure change at 12 months
increases
and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline
PMID 28236285 · one of two readings recorded this
diastolic blood pressure change at 24 months
no effect
There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure change at 6 months
increases
Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure change at first measurement
increases
(average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure change at first measurement
increases
A peak in DBP (mean +1.7 mmHg) and HR (mean +3.7 bpm) was reported at the first measurement (average 3.2 months after baseline)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post, effect of study duration
increases
Studies <18 weeks reported higher ESs (SMD 0.28) compared with longer duration studies (SMD 0.05)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post, effect of study duration
increases
Studies <18 weeks reported higher ESs (SMD 0.28) compared with longer duration studies (SMD 0.05)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post, moderator test of study duration
modulates, p = 0.05
Sensitivity analyses revealed a significant effect of study duration on DBP following AMP treatment (F(1) = 19.55, p = 0.05)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post
increases, p = 0.01
a small but statistically significant increase in DBP associated with ADHD medication (SMD 0.18, 95% CI 0.09–0.26, p < 0.01; 17 studies)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post
increases, p = 0.02
AMP (SMD 0.16, 95% confidence interval [CI] 0.03–0.29, p = 0.02; four studies)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post
increases, p = 0.01
ATX (SMD 0.22, 95% CI 0.10–0.34, p < 0.01; seven studies)
PMID 28236285 · one of two readings recorded this
diastolic blood pressure pre-post
no effect, p = 0.11
The effect for MPH was not significant (SMD 0.16, 95% CI −0.04 to 0.36, p = 0.11; ten studies)
PMID 28236285 · one of two readings recorded this
heart rate change at 12 months
increases
and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline
PMID 28236285 · one of two readings recorded this
heart rate change at 24 months
no effect
There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)
PMID 28236285 · one of two readings recorded this
heart rate change at 6 months
increases
Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)
PMID 28236285 · one of two readings recorded this
heart rate change at first measurement
increases
(average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)
PMID 28236285 · one of two readings recorded this
heart rate change at first measurement
increases
A peak in DBP (mean +1.7 mmHg) and HR (mean +3.7 bpm) was reported at the first measurement (average 3.2 months after baseline)
PMID 28236285 · one of two readings recorded this
heart rate pre-post
increases, p = 0.01
Pooled pre–post effects across all three medications were small but statistically significant (SMD 0.32, 95% CI 0.20–0.43, p < 0.01; 17 studies)
PMID 28236285 · one of two readings recorded this
heart rate pre-post
increases, p = 0.01
AMP (SMD 0.37, 95% CI 0.13–0.60, p < 0.01; five studies)
PMID 28236285 · one of two readings recorded this
heart rate pre-post
increases, p = 0.01
ATX (SMD 0.43, 95% CI 0.26–0.60, p < 0.01; seven studies)
PMID 28236285 · one of two readings recorded this
heart rate pre-post
no effect, p = 0.07
the effects for MPH were not statistically significant (SMD 0.20, 95% CI −0.02 to 0.41, p = 0.07; 10 studies)
PMID 28236285 · one of two readings recorded this
other cardiovascular effects, difference between medications
no effect, p = 0.007
There were no significant differences between the medication treatments, (F(2) = 3.006, p = 0.007)
PMID 28236285 · one of two readings recorded this
pre-post change in systolic and diastolic blood pressure and heart rate on methylphenidate, amphetamines and atomoxetine in children with ADHD (medication arms only, pre-post SMD)
increases, MPH SBP pre-post SMD 0.25, 95% CI 0.08-0.42
Not recorded as a finding: the result compares a group with itself, not with a control
MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials), AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies) and ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies) each had small but statistically significant pre–post effects on SBP.
PMID 28236285 · one of two readings recorded this
pre-post change in systolic blood pressure, diastolic blood pressure and heart rate on methylphenidate, standardised mean difference of within-group change; setting not stated
increases, SBP pre-post SMD 0.25, 95% CI 0.08-0.42 for MPH
Not recorded as a finding: the result compares a group with itself, not with a control
MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials), AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies) and ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies) each had small but statistically significant pre–post effects on SBP.
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at 12 months
no effect
Arcieri et al. reported no statistically significant effects on DBP (+0.13 mmHg) and SBP (+0.36 mmHg) at 12 months in comparison with baseline
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at 12 months
increases
and at 12 months (DBP +1.6 mmHg; SBP +1.6 mmHg; HR +5.6 bpm) compared with baseline
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at 24 months
no effect
There were no statistically significant effects at 24 months in comparison with the baseline (DBP +1.11 mmHg; SBP +2.13 mmHg; HR +0.21 bpm)
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at 6 months
increases
Fuentes et al. observed small changes at 6 months for all cardiovascular parameters (DBP +1.3 mmHg; SBP +0.8 mmHg; HR +7.9 bpm)
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at first measurement
increases
(average 6 weeks; mean changes: DBP +1 mmHg; SBP +0.75 mmHg; HR +3.35 bpm)
PMID 28236285 · one of two readings recorded this
systolic blood pressure change at first measurement
increases
Similar results were reported on SBP (mean +1.6 mmHg)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post, effect of publication year
no effect
Studies published before 2007 reported higher ESs (SMD 0.37) than studies after 2007 (SMD −0.02)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post, effect of publication year
increases
Studies published before 2007 reported higher ESs (SMD 0.37) than studies after 2007 (SMD −0.02)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post, moderator test of publication year
modulates, p = 0.05
There was a significant effect of publication year on SBP for MPH treatment (F(1) = 5.346, p = 0.05)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post
increases, p = 0.01
Across all medications together there was a small and significant pre–post effect (SMD 0.18, 95% CI 0.10–0.27, p < 0.01; 17 studies)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post
increases, p = 0.01
AMP (SMD 0.09, 95% CI 0.03–0.15, p < 0.01; four studies)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post
increases, p = 0.01
ATX (SMD 0.16, 95% CI 0.04–0.27, p = 0.01; seven studies)
PMID 28236285 · one of two readings recorded this
systolic blood pressure pre-post
increases, p = 0.01
MPH (SMD 0.25, 95% CI 0.08–0.42, p < 0.01; ten trials)
PMID 28236285 · one of two readings recorded this
abdominal pain, parallel group vs cross-over trials
no effect, p = 0.23
we found no difference in the risk of abdominal pain between parallel group and cross-over trials (P=0.23; Fig 5)
PMID 28617801 · one of two readings recorded this
abdominal pain, subgroup difference by dose
no effect, p = 0.95
abdominal pain (P=0.95)
PMID 28617801 · one of two readings recorded this
abdominal pain, subgroup difference by type
no effect, p = 0.72
abdominal pain (P=0.72)
PMID 28617801 · one of two readings recorded this
abdominal pain, subgroup difference short-term vs long-term
no effect, p = 0.18
abdominal pain (P=0.18)
PMID 28617801 · one of two readings recorded this
abdominal pain
increases, n = 1837
increased abdominal pain (RR 1.61; 95% CI 1.27 to 2.04; 1,837 participants; 33 trials, Fig 5)
PMID 28617801 · one of two readings recorded this
abdominal pain
no effect
abdominal pain (RR 1.30; 95% CI 1.00 to 1.69; 13 trials)
PMID 28617801 · one of two readings recorded this
decreased appetite, low dose
no effect
low dose (RR 2.87; 95% CI 0.87 to 9.45)
PMID 28617801 · one of two readings recorded this
decreased appetite, moderate/high dose
increases, p = 0.86
moderate/high dose (RR 2.57; 95% CI 1.96 to 3.35), (test for subgroup differences: P=0.86)
PMID 28617801 · one of two readings recorded this
decreased appetite, parallel-group vs cross-over trials
no effect, p = 0.41
We found no significant difference in the risk of the main outcome decreased appetite between parallel-group and cross-over trials (P = 0.41; I2 = 0%; Fig 2)
PMID 28617801 · one of two readings recorded this
decreased appetite, subgroup difference by type
no effect, p = 0.11
decreased appetite (P=0.11)
PMID 28617801 · one of two readings recorded this
decreased appetite, subgroup difference short-term vs long-term
no effect, p = 0.53
decreased appetite (P=0.53)
PMID 28617801 · one of two readings recorded this
decreased appetite
increases, n = 1901
We found that methylphenidate decreased appetite (RR 3.04; 95% CI 2.35 to 3.94; 1,901 participants; 36 trials, Fig 2)
PMID 28617801 · one of two readings recorded this
decreased appetite
increases, n = 2962
In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2)
PMID 28617801 · one of two readings recorded this
decreased weight, subgroup difference by dose
no effect, p = 0.72
decreased weight (P=0.72)
PMID 28617801 · one of two readings recorded this
decreased weight, subgroup difference by type
no effect, p = 0.28
decreased weight (P=0.28)
PMID 28617801 · one of two readings recorded this
decreased weight
increases, n = 859
decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3)
PMID 28617801 · one of two readings recorded this
diarrhea, subgroup difference by dose
no effect, p = 0.94
diarrhea (P=0.94)
PMID 28617801 · one of two readings recorded this
diarrhoea
no effect
diarrhoea (RR 1.07; 95% CI 0.41 to 2.77; 5 trials)
PMID 28617801 · one of two readings recorded this
dyspepsia, subgroup difference by type
no effect, p = 0.98
dyspepsia (P=0.98)
PMID 28617801 · one of two readings recorded this
dyspepsia, subgroup difference short-term vs long-term
no effect, p = 0.98
dyspepsia (P=0.98)
PMID 28617801 · one of two readings recorded this
dyspepsia
no effect
dyspepsia (RR 1.80; 95% CI 0.71 to 4.54; 2 trials)
PMID 28617801 · one of two readings recorded this
Egger test publication bias, abdominal pain
no effect, p = 0.136
Egger’s regression intercept (bias) was 1.11 (two-tailed P = 0.136)
PMID 28617801 · one of two readings recorded this
Egger test publication bias, decreased appetite
unclear, p = 0.02
Eggers’ regression intercept (bias) was 8.717 (two-tailed P = 0.020)
PMID 28617801 · one of two readings recorded this
Egger test publication bias, nausea
no effect, p = 0.215
Egger’s regression intercept (bias) was 2.16 (two-tailed P = 0.215)
PMID 28617801 · one of two readings recorded this
Egger test publication bias, vomiting
no effect, p = 0.271
Egger’s regression intercept (bias) was 1.438 (two-tailed P = 0.271)
PMID 28617801 · one of two readings recorded this
increased appetite
increases, n = 68
One trial observed that methylphenidate increased appetite (RR 0.20; 95% CI 0.08 to 0.50; 68 participants; 1 trial)
PMID 28617801 · one of two readings recorded this
increased appetite
no effect
increased appetite (RR 0.07; 95% CI 0.00 to 1.43; 1 trial)
PMID 28617801 · one of two readings recorded this
nausea, subgroup difference by dose
no effect, p = 0.63
nausea (P=0.63)
PMID 28617801 · one of two readings recorded this
nausea, subgroup difference by type
no effect, p = 0.2
nausea (P=0.20)
PMID 28617801 · one of two readings recorded this
nausea, subgroup difference short-term vs long-term
no effect, p = 0.38
nausea (P=0.38)
PMID 28617801 · one of two readings recorded this
nausea
no effect
nausea (RR 1.30; 95% CI 0.85 to 1.99; 11 trials)
PMID 28617801 · one of two readings recorded this
risk of decreased appetite, decreased weight, abdominal pain and other gastrointestinal adverse events, pooled risk ratio versus placebo or no intervention
increases, decreased appetite RR 3.66; 95% CI 2.56 to 5.23 in parallel group trials
Not recorded as a finding: this platform holds no node for the endpoint
In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2) and decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3).
PMID 28617801 · one of two readings recorded this
risk of individual gastrointestinal adverse events (decreased appetite, decreased weight, abdominal pain, nausea, vomiting, diarrhoea, dyspepsia) vs placebo or no intervention, pooled risk ratios
increases, decreased appetite RR 3.66, 95% CI 2.56 to 5.23
Not recorded as a finding: this platform holds no node for the endpoint
In parallel group trials methylphenidate was associated with decreased appetite (RR 3.66; 95% CI 2.56 to 5.23; 2,962 participants; 16 trials, Fig 2) and decreased weight (RR 3.89; 95% CI 1.43 to 10.59; 859 participants; 7 trials, Fig 3).
PMID 28617801 · one of two readings recorded this
Trial Sequential Analysis required information size, abdominal pain
For abdominal pain the required information size was 4,830 participants
PMID 28617801 · one of two readings recorded this
Trial Sequential Analysis required information size, decreased appetite
For the outcome decreased appetite the required information size was 14,286 participants
PMID 28617801 · one of two readings recorded this
vomiting, subgroup difference by dose
no effect, p = 0.68
vomiting (P=0.68)
PMID 28617801 · one of two readings recorded this
vomiting, subgroup difference by type
no effect, p = 0.85
vomiting (P=0.85)
PMID 28617801 · one of two readings recorded this
vomiting, subgroup difference short-term vs long-term
no effect, p = 0.95
vomiting (P=0.95)
PMID 28617801 · one of two readings recorded this
vomiting
no effect
vomiting (RR 1.17; 95% CI 0.76 to 1.79; 11 trials)
PMID 28617801 · one of two readings recorded this
hyperactivity, parent-rated
decreases, p = 0.02, n = 71
and parents (mean difference (MD) -6.61 points, 95% CI -12.19 to -1.03, rated on the hyperactivity subscale of the Aberrant Behviour Checklist, range 0 to 48; 2 studies, 71 participants; P = 0.02; low-quality evidence)
PMID 29159857 · one of two readings recorded this
hyperactivity, teacher-rated
decreases, p = 0.001, n = 73
hyperactivity, as rated by teachers (SMD -0.78, 95% confidence interval (CI) -1.13 to -0.43; 4 studies, 73 participants; P < 0.001; low-quality evidence)
PMID 29159857 · one of two readings recorded this
inattention, teacher-rated
decreases, p = 0.04, n = 51
teacher-rated inattention (MD -2.72 points, 95% CI -5.37 to -0.06, rated on the inattention subscale of the Swanson, Nolan and Pelham, Fourth Version questionnaire, range 0 to 27; 2 studies, 51 participants; P = 0.04; low-quality evidence)
PMID 29159857 · one of two readings recorded this
overall ASD, teacher-rated
no effect, p = 0.15, n = 36
or overall ASD (SMD -0.53, 95% CI -1.26 to 0.19; 2 studies, 36 participants; P = 0.15; low-quality evidence)
PMID 29159857 · one of two readings recorded this
reduced appetite, parent-rated
increases, p = 0.001, n = 74
reduced appetite as rated by parents (risk ratio 8.28, 95% CI 2.57 to 26.73; 2 studies, 74 participants; P < 0.001; very low-quality evidence)
PMID 29159857 · one of two readings recorded this
social interaction, teacher-rated
no effect, p = 0.07, n = 63
or benefits social interaction (SMD -0.51, 95% CI -1.07 to 0.05; 3 studies, 63 participants; P = 0.07; very low-quality evidence)
PMID 29159857 · one of two readings recorded this
stereotypical behaviours, teacher-rated
no effect, p = 0.19, n = 69
stereotypical behaviours (SMD -0.34, 95% CI -0.84 to 0.17; 3 studies, 69 participants; P = 0.19; low-quality evidence)
PMID 29159857 · one of two readings recorded this
teacher- and parent-rated hyperactivity (SMD; Aberrant Behavior Checklist hyperactivity subscale), teacher-rated inattention (SNAP-IV inattention subscale), ASD core symptoms, parent-rated reduced appetite
increases, reduced appetite RR 8.28, 95% CI 2.57 to 26.73
Not recorded as a finding: this platform holds no node for the endpoint
The only adverse effect that was significantly more likely with treatment was reduced appetite as rated by parents (risk ratio 8.28, 95% CI 2.57 to 26.73; 2 studies, 74 participants; P < 0.001; very low-quality evidence).
PMID 29159857 · one of two readings recorded this
Egger regression publication bias, rs6551665 (LPHN3) and SLC6A3 10-repeat VNTR
unclear, p = 0.01
Egger’s regression tests detected significant publication bias (asymmetry) for both DNA variants (P = 0.01)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, 10-repeat VNTR (SLC6A3)
p = 0.0001
10-repeat VNTR (SLC6A3) (χ2 = 47.37, P < 0.0001; I2 = 68%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, 4-repeat VNTR (DRD4)
p = 0.14
4-repeat VNTR (DRD4) (χ2 = 8.23, P = 0.14; I2 = 39%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, 7-repeat VNTR (DRD4)
p = 0.02
7-repeat VNTR (DRD4) (χ2 = 11.36, P = 0.02; I2 = 65%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs1800544 (ADRA2A)
p = 0.002
rs1800544 (ADRA2A) (χ2 = 14.73, P = 0.002; I2 = 80%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs1947274 (LPHN3)
p = 0.005
rs1947274 (LPHN3) (χ2= 10.44, P = 0.005; I2 = 81%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs28386840 (SLC6A2)
p = 0.34
rs28386840 (SLC6A2) (χ2 = 2.18, P = 0.34; I2 = 8%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs4680 (COMT)
p = 0.003
rs4680 (COMT) (χ2 = 19.96, P = 0.003; I2 = 70%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs5569 (SLC6A2)
p = 0.43
rs5569 (SLC6A2) (χ2 = 5.92, P = 0.43; I2 = 0%)
PMID 29230023 · one of two readings recorded this
Heterogeneity I2, rs5661665 (LPHN3)
p = 0.005
rs5661665 (LPHN3) (χ2 = 12.96, P = 0.005; I2 = 77%)
PMID 29230023 · one of two readings recorded this
Meta-regression of effect size on study quality, all significant variants without publication bias
no effect, p = 0.4885
This analysis found no significant effect size associations with MPH response (k = 55, b = 0.0626, P = 0.4885)
PMID 29230023 · one of two readings recorded this
MPH response by DRD4 48bp VNTR 4-repeat homozygous vs other genotypes
increases, p = 0.005
The homozygous 4-repeat genotype demonstrated an association with improved MPH response when compared to other genotypes (OR: 1.66, CI: 1.16–2.37, P = 0.005)
PMID 29230023 · one of two readings recorded this
MPH response by DRD4 VNTR 7-repeat allele vs others
no effect, p = 0.05
meta-analysis of the 7-repeat allele versus others did not reach statistical significance (OR: 0.68, CI: 0.47–1.00, P = 0.05)
PMID 29230023 · one of two readings recorded this
MPH response by rs1800544 (ADRA2A) G allele vs C allele carriers
increases, p = 0.01
Furthermore, the G allele of rs1800544 (ADRA2A) was associated with improved MPH response compared to C allele carriers (OR: 1.69, CI: 1.12–2.55, P = 0.01)
PMID 29230023 · one of two readings recorded this
MPH response by rs1947274 (LPHN3)
no effect, p = 0.7
Two variants within the LPHN3 gene were not significantly associated with MPH response: rs5661665 (OR: 1.07, CI: 0.84–1.37, P = 0.59) and rs1947274 (OR: 0.95, CI: 0.71–1.26, P = 0.70)
PMID 29230023 · one of two readings recorded this
MPH response by rs2284411 (GRIN2B) C/C genotype
increases, p = 0.05
The C/C genotype of rs2284411 (GRIN2B) was associated with improved MPH treatment response (OR: 9.03, CI: 1.02–79.99, P = 0.05)
PMID 29230023 · one of two readings recorded this
MPH response by rs28386840 (SLC6A2) T allele vs A/A genotype
increases, p = 0.0001
For rs28386840 (SLC6A2), the T allele was associated with an improved response to MPH treatment when compared to the A/A genotype (OR: 2.93, CI: 1.76–4.90, P < 0.0001)
PMID 29230023 · one of two readings recorded this
MPH response by rs3746544 (SNAP25) T/T genotype, first study
no effect, p = 0.86
the T/T genotype of rs3746544 (SNAP25) was not significantly associated with treatment response in two studies (OR:1.12, CI: 0.55–2.25, P = 0.86;OR: 1.66, CI: 0.51–5.39, P = 0.41)
PMID 29230023 · one of two readings recorded this
MPH response by rs3746544 (SNAP25) T/T genotype, second study
no effect, p = 0.41
the T/T genotype of rs3746544 (SNAP25) was not significantly associated with treatment response in two studies (OR:1.12, CI: 0.55–2.25, P = 0.86;OR: 1.66, CI: 0.51–5.39, P = 0.41)
PMID 29230023 · one of two readings recorded this
MPH response by rs4680 (COMT) Val/Val genotype vs Met allele carriers
increases, p = 0.02
Meta-analysis of the rs4680 variant in COMT revealed that the Val/Val genotype was associated with improved treatment response compared with Met allele carriers (OR: 1.40, CI: 1.04–1.87, P = 0.02)
PMID 29230023 · one of two readings recorded this
MPH response by rs5569 (SLC6A2) G/G genotype vs A allele carriers
increases, p = 0.0007
The G/G genotype of rs5569 (SLC6A2) was associated with an improved MPH response compared to A allele carriers (OR: 1.73, CI: 1.26–2.37, P = 0.0007)
PMID 29230023 · one of two readings recorded this
MPH response by rs5661665 (LPHN3)
no effect, p = 0.59
Two variants within the LPHN3 gene were not significantly associated with MPH response: rs5661665 (OR: 1.07, CI: 0.84–1.37, P = 0.59) and rs1947274 (OR: 0.95, CI: 0.71–1.26, P = 0.70)
PMID 29230023 · one of two readings recorded this
MPH response by rs6265 (BDNF) Val/Val genotype
no effect, p = 0.07
The Val/Val genotype of rs6265 (BDNF) was not significantly associated with MPH response, despite having a substantial effect size (OR: 6.67, CI: 0.84–52.89, P = 0.07)
PMID 29230023 · one of two readings recorded this